{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(4)"],"submitter":["Palazzolo JS"],"pubmed_abstract":["Thrombolysis with tissue-type plasminogen activator (tPA) remains the main treatment for acute ischemic stroke. Nevertheless, tPA intervention is limited by a short therapeutic window, low recanalization rates, and a risk of intracranial hemorrhage (ICH), highlighting the clinical demand for improved thrombolytic drugs. We examined a novel thrombolytic agent termed \"SCE5-scuPA,\" comprising a single-chain urokinase plasminogen activator (scuPA) fused with a single-chain antibody (SCE5) that targets the activated glycoprotein IIb/IIIa platelet receptor, for its effects in experimental stroke. SCE5-scuPA was first tested in a whole blood clot degradation assay to show the benefit of platelet-targeted thrombolysis. The tail bleeding time, blood clearance, and biodistribution were then determin"],"journal":["Blood advances"],"pagination":["561-574"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9984306"],"repository":["biostudies-literature"],"pubmed_title":["Platelet-targeted thrombolysis for treatment of acute ischemic stroke."],"pmcid":["PMC9984306"],"pubmed_authors":["Alt K","Jagdale S","Broughton BRS","Wright DK","Hagemeyer CE","Palazzolo JS","Niego B","Medcalf RL","Ale A","Ho H"],"additional_accession":[]},"is_claimable":false,"name":"Platelet-targeted thrombolysis for treatment of acute ischemic stroke.","description":"Thrombolysis with tissue-type plasminogen activator (tPA) remains the main treatment for acute ischemic stroke. Nevertheless, tPA intervention is limited by a short therapeutic window, low recanalization rates, and a risk of intracranial hemorrhage (ICH), highlighting the clinical demand for improved thrombolytic drugs. We examined a novel thrombolytic agent termed \"SCE5-scuPA,\" comprising a single-chain urokinase plasminogen activator (scuPA) fused with a single-chain antibody (SCE5) that targets the activated glycoprotein IIb/IIIa platelet receptor, for its effects in experimental stroke. SCE5-scuPA was first tested in a whole blood clot degradation assay to show the benefit of platelet-targeted thrombolysis. The tail bleeding time, blood clearance, and biodistribution were then determin","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-05-29T16:30:27.09Z","creation":"2025-04-06T12:22:43.212Z"},"accession":"S-EPMC9984306","cross_references":{"pubmed":["35482909"],"doi":["10.1182/bloodadvances.2021006691"]}}